Ideaya Biosciences price target raised to $30 from $26 at Oppenheimer

Oppenheimer raised the firm’s price target on Ideaya Biosciences to $30 from $26 and keeps an Outperform rating on the shares after the company held a call to discuss updates from its darovasertib franchise in uveal melanoma. The analyst says that with nearly twice as many patients since last September, it has not seen "telltale signs of a reversion back to the mean." Durability has actually improved, says the firm, who increases its probability of success for darovasertib plus crizotinib to 75% from 40%.